TriangleNCT02677324 · OUTCOME
Progression Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 4 years
What was measured
Amount of time following ABT-199 administration until \>25% increase in serum IgM
Analysis population: 1 participant was censored from the response analysis after it was determined that he had IgM Myeloma rather than Waldenstrom's macroglobulinemia.
Groups in this outcome
ABT199
ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles ABT199: Oral BCL-2 antagonist
| Group | Source count |
|---|---|
| ABT199 | 32 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ABT199 | 31.5 | Not reported | 26.6 | 38.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 26.6
- upper Limit
- 38.6
- value
- 31.5
- denoms
- counts
- group Id
- OG000
- value
- 32
- units
- Participants
- description
- Amount of time following ABT-199 administration until \>25% increase in serum IgM
- dispersion Type
- 95% Confidence Interval
- groups
- description
- ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles ABT199: Oral BCL-2 antagonist
- id
- OG000
- title
- ABT199
- param Type
- MEDIAN
- population Description
- 1 participant was censored from the response analysis after it was determined that he had IgM Myeloma rather than Waldenstrom's macroglobulinemia.
- reporting Status
- POSTED
- time Frame
- 4 years
- title
- Progression Free Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice